Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8.48	25.03	25.84	92.94	106.08
Short-Term Investments	-	17.47	25.88	149.88	264.98
Cash & Short-Term Investments	8.48	42.5	51.73	242.82	371.07
Cash Growth	-80.04%	-17.84%	-78.70%	-34.56%	-25.88%
Accounts Receivable	1.25	1.48	34.11	40.22	0.99
Inventory	-	10.66	9.71	1.59	-
Other Current Assets	2.48	10.26	6.33	10.45	12.57
Total Current Assets	12.21	64.89	101.87	295.08	384.62
Net Property, Plant & Equipment	7.14	41.1	58.79	74.32	79.94
Other Long-Term Assets	0.89	3.1	4.84	7.02	3.57
Total Assets	20.24	109.1	165.5	376.42	468.13
Accounts Payable	0.13	4.37	3.68	6.87	17.37
Accrued Expenses	1.35	14.57	28.88	42.65	38.6
Unearned Revenue	0.72	95.09	77.83	8	40.76
Other Current Liabilities	12.73	20.54	31.83	21.39	9.06
Total Current Liabilities	14.92	134.57	142.23	78.92	105.79
Long-Term Leases	9.35	29.91	45.69	58.06	25.52
Other Long-Term Liabilities	34.47	41.89	76.82	112.8	57.21
Total Long-Term Liabilities	43.82	71.81	122.51	170.86	82.73
Total Liabilities	58.74	206.38	264.74	249.78	188.51
Common Stock	0	0	-	0.01	0.01
Additional Paid-in Capital	1,983	1,957	1,870	1,822	1,745
Accumulated Other Comprehensive Income	0	0.01	-0.2	-2.07	-0.37
Retained Earnings	-2,022	-2,055	-1,969	-1,693	-1,465
Shareholders' Equity	-38.5	-97.28	-99.23	126.64	279.61
Total Liabilities & Equity	20.24	109.1	165.5	376.42	468.13
Total Debt	9.35	29.91	45.69	58.06	25.52
Net Cash (Debt)	-0.87	12.58	6.03	184.76	345.55
Net Cash Growth	-	108.59%	-96.73%	-46.53%	-29.13%
Net Cash Per Share	-0.07	1.68	1.42	45.29	92.22
Book Value	-38.5	-97.28	-99.23	126.64	279.61
Book Value Per Share	-3.03	-12.99	-23.43	31.04	74.63
Tangible Book Value	-38.5	-97.28	-99.23	126.64	279.61
Tangible Book Value Per Share	-3.03	-12.99	-23.43	31.04	74.63

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q